Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has a previous diagnosis of multiple myeloma.~2. Patient requires retreatment for multiple myeloma~3. Patient has measurable M component in serum or urine at study screening~Exclusion Criteria:~1. Patient who has progressed under all prior lines of anti MM therapy~2. Patient who has been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose~3. Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug , following locally applicable prescribing information~4. Patient received prior treatment with DAC inhibitors including panobinostat~5. Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG~6. Patient taking medications with relative risk of prolonging the QT interval or inducing Torsade de pointes~7. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panobinostat + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): None
- Placebo + Bortezomib + Dexamethasone (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).